PaxVax appoints three new senior leaders
The appointments of Linda Rubinstein as chief financial officer, Piers Whitehead as chief corporate development officer and Thomas Yonker as vice president of project management were part of an expansion of PaxVax's commercial leadership team.
"I am very pleased to welcome Linda, Piers, and Tom to the PaxVax team," Kenneth Kelley, the CEO of PaxVax, said. "All are accomplished business executives who bring to the company decades of biologics, vaccines, and business expertise."
PaxVax developed a clinical-stage product portfolio, including PXVX0200, the company's lead product. PXVX0200 is an oral, single-dose cholera vaccine now completing Phase III clinical trials. The drug candidate was granted fast track designation by the U.S. Food and Drug Administration.
"Currently, no single-dose cholera vaccine is available in the world today," Kelley said. "In anticipation of U.S. regulatory approval of PXVX0200, we believe the cumulative experience of Linda, Piers, and Tom will help PaxVax successfully transition our candidate vaccines from (research and development) to commercialization."
PaxVax's biodefense specialty pipeline also includes a pandemic H5N1 influenza vaccine and an anthrax vaccine.